C
Claudia Leemereise
Researcher at GlaxoSmithKline
Publications - 4
Citations - 120
Claudia Leemereise is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Placebo & COPD. The author has an hindex of 3, co-authored 4 publications receiving 82 citations.
Papers
More filters
Journal ArticleDOI
Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD
Anthony Cahn,Julie Nicole Hamblin,Malcolm Begg,Robert Wilson,L. Dunsire,Srividya Sriskantharajah,Mickael Montembault,Claudia Leemereise,L. Galinanes-Garcia,Henrik Watz,Anne Kirsten,Rainard Fuhr,Edith M. Hessel +12 more
TL;DR: In inhaled GSK2269557 had an acceptable safety profile for progression into larger studies in COPD patients and resulted in suppression of sputum IL-8 and IL-6 levels, consistent with the known anti-inflammatory activity of a PI3Kδ inhibitor.
Journal ArticleDOI
A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Sanjeev Khindri,Anthony Cahn,Malcolm Begg,Mickael Montembault,Claudia Leemereise,Yi Cui,Annabel Hogg,Hannah Wajdner,Shuying Yang,Jon Robertson,J. Nicole Hamblin,Andrea Ludwig-Sengpiel,Oliver Kornmann,Edith M. Hessel +13 more
TL;DR: The results suggest that nemiralisib inhibited PI3Kδ locally; however, this did not translate into meaningful clinical improvement, and further studies will investigate the potential efficacy of nemiral isib in patients with asthma with other specific more severe phenotypes, including those who are colonized with bacteria and frequently exacerbate.
Journal ArticleDOI
Safety, Tolerability, and Pharmacokinetics of a New Formulation of Nemiralisib Administered via a Dry Powder Inhaler to Healthy Individuals.
Robert Wilson,Alison Templeton,Claudia Leemereise,Rhena Eames,Edward Banham-Hall,Edith M. Hessel,Anthony Cahn +6 more
TL;DR: After single-dose inhalation of 500 and 750 μg of nemiralisib from the Ellipta DPI in healthy individuals, plasma PK data were well defined, and as predicted based on previous PK and APSD data, exposure was increased with the new formulation.
Journal ArticleDOI
An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial
Anthony Cahn,J. Nicole Hamblin,Jon Robertson,Malcolm Begg,Emily Jarvis,Robert Wilson,Gordon J. Dear,Claudia Leemereise,Yi Cui,Maki Mizuma,Mickael Montembault,Cedric Van Holsbeke,Wim Vos,Wilfried De Backer,Jan De Backer,Edith M. Hessel +15 more
TL;DR: In this paper, the authors evaluated the safety and efficacy of inhaled nemiralisib, a PI3K inhibitor, in patients with an acute exacerbation of chronic obstructive pulmonary disease (COPD).